| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 72,390 | $70 | $4.7M |
| J2315 | Injection, naltrexone, depot form, 1 mg | 3,570 | $1,150 | $4.1M |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 6,410 | $90 | $570.3K |
| 99204 | The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider… | 3,120 | $120 | $359.1K |
| 99203 | The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the provider… | 4,200 | $80 | $323.5K |
| Q9992 | Injection, buprenorphine extended-release (sublocade), greater than 100 mg | 190 | $1,700 | $320.9K |
| 99385 | The provider performs a well–patient visit for a patient who is between the ages of 18 and 39. | 2,140 | $100 | $205.1K |
| 99395 | The provider performs an established well–patient visit for a patient who is between the ages of 18 and 39. | 1,670 | $90 | $149K |
| 99396 | The provider performs an established well–patient visit for a patient who is between the ages of 40 and 64. | 1,470 | $100 | $145.9K |
| 87635 | Using an amplified nucleic acid probe technique, the lab analyst performs the necessary steps to identify the nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–COV–2) virus… | 3,110 | $40 | $130.5K |